[go: up one dir, main page]

TR200002496T2 - Gen Terapisinde Ateşli Hücrelerin Kendinden Ayarlı Apoptosisi. - Google Patents

Gen Terapisinde Ateşli Hücrelerin Kendinden Ayarlı Apoptosisi.

Info

Publication number
TR200002496T2
TR200002496T2 TR2000/02496T TR200002496T TR200002496T2 TR 200002496 T2 TR200002496 T2 TR 200002496T2 TR 2000/02496 T TR2000/02496 T TR 2000/02496T TR 200002496 T TR200002496 T TR 200002496T TR 200002496 T2 TR200002496 T2 TR 200002496T2
Authority
TR
Turkey
Prior art keywords
cells
apoptosis
chimeric nucleic
self
fever
Prior art date
Application number
TR2000/02496T
Other languages
English (en)
Inventor
J. Tatake Revati
D. Marlin Steven
W. Barton Randall
Original Assignee
Boehringer Ingelheim Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals, Inc. filed Critical Boehringer Ingelheim Pharmaceuticals, Inc.
Publication of TR200002496T2 publication Critical patent/TR200002496T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Bu bulus, kimerik nükleik asitler ve aktif iltihap hücrelerinde ya da iltihapli bir bölgedeki hücrelerde apoptozun tedavi edici endüklenmesi ile ilgilidir ki söz konusu endükleme, bu hücrelere kimerik nükleik asidin dahil edilmesi ile gerçeklestirilir. En az bir TNFalfa özendirici zenginlestirici ihtiva eden kimerik nükleik asit, bir TNFalfa özendiricinin bir fonksiyonel kopyasina ve kendi de bir 3'UTR'ye bagli en az bir apoptoz-endükleyici gen kopyasina baglanir. Apoptoz endükleyen gen Granzim B'dir.Bulus ayrica kendi kendini düzenleyen apoptoz kimerik nükleik asitleri ve iltihapli hastaliklari tedavi etmek için bunlari ihtiva eden ispençiyari müstahzarlari hazirlamak için yöntemler ile de ilgilidir..
TR2000/02496T 1998-02-27 1999-01-12 Gen Terapisinde Ateşli Hücrelerin Kendinden Ayarlı Apoptosisi. TR200002496T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7631698P 1998-02-27 1998-02-27

Publications (1)

Publication Number Publication Date
TR200002496T2 true TR200002496T2 (tr) 2000-11-21

Family

ID=22131220

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02496T TR200002496T2 (tr) 1998-02-27 1999-01-12 Gen Terapisinde Ateşli Hücrelerin Kendinden Ayarlı Apoptosisi.

Country Status (18)

Country Link
US (1) US6537784B1 (tr)
EP (1) EP1056877A1 (tr)
JP (1) JP2002504381A (tr)
KR (1) KR20010086587A (tr)
CN (1) CN1292032A (tr)
AR (1) AR014661A1 (tr)
AU (1) AU761497B2 (tr)
BR (1) BR9909250A (tr)
CA (1) CA2321178A1 (tr)
CO (1) CO4820446A1 (tr)
HU (1) HUP0100776A3 (tr)
IL (1) IL137871A0 (tr)
NZ (1) NZ506941A (tr)
PE (1) PE20000335A1 (tr)
PL (1) PL343248A1 (tr)
TR (1) TR200002496T2 (tr)
WO (1) WO1999043840A1 (tr)
ZA (1) ZA991519B (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040039186A1 (en) * 1997-02-28 2004-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP2004535202A (ja) 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
US6867237B1 (en) * 2001-07-23 2005-03-15 Senesco Technologies, Inc. DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans
ES2340270T3 (es) * 2002-08-23 2010-06-01 Gabriele Prof. Dr. Multhoff Granzima b dependiente de peptidos hsp70/hsp70 como inductora de apoptosis en celulas tumorales.
AU2003275173A1 (en) * 2002-09-25 2004-04-19 Board Of Regents, The University Of Texas System Endogenous granzyme b in human non-hematopoietic cells
EP2428218A1 (en) * 2005-10-21 2012-03-14 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
NZ584848A (en) * 2007-09-28 2012-09-28 Intrexon Corp Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01137976A (ja) * 1987-11-20 1989-05-30 Asahi Chem Ind Co Ltd 新規ｄｎａフラグメント
US5792751A (en) 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
AU684050B2 (en) * 1992-07-13 1997-12-04 Baylor College Of Medicine Targeting somatic gene therapy to joints
IL107250A (en) * 1993-10-12 2001-08-08 Yeda Res & Dev Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins
US5744304A (en) 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
US6004942A (en) 1995-08-30 1999-12-21 The Regents Of The University Of California Methods for treating arthritis by administering an apoptosis regulator
IL131328A0 (en) 1997-02-28 2001-01-28 Boehringer Ingelhem Pharmaceut Self-regulated apoptosis of inflammatory cells by gene therapy

Also Published As

Publication number Publication date
AR014661A1 (es) 2001-03-28
IL137871A0 (en) 2001-10-31
JP2002504381A (ja) 2002-02-12
BR9909250A (pt) 2001-09-04
KR20010086587A (ko) 2001-09-13
CN1292032A (zh) 2001-04-18
HUP0100776A3 (en) 2003-08-28
HUP0100776A2 (hu) 2001-06-28
AU2113299A (en) 1999-09-15
US6537784B1 (en) 2003-03-25
NZ506941A (en) 2004-01-30
WO1999043840A1 (en) 1999-09-02
ZA991519B (en) 1999-11-23
EP1056877A1 (en) 2000-12-06
CA2321178A1 (en) 1999-09-02
PE20000335A1 (es) 2000-04-26
PL343248A1 (en) 2001-07-30
CO4820446A1 (es) 1999-07-28
AU761497B2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
Wu et al. Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats
DE69535853D1 (de) Kompaktnukleinsäure und ihre verabreichung in zellen
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
CY1107951T1 (el) Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α
DE69830663D1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
AU5161800A (en) Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
TR199902731T2 (tr) Kimyasal bilesikler.
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
DE69628864D1 (de) Invertierte chimäre und hybrid-oligonukleotide
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
DE69321729D1 (de) Aminosäure-gebundene senfgas derivate und ihre verwendung als wirkstoffvorstufe in der behandlung von tumoren
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
WO1995021927A3 (en) Targeting gene therapy
HUT76511A (en) Benzoyl derivatives, preparation and use thereot
TR200002496T2 (tr) Gen Terapisinde Ateşli Hücrelerin Kendinden Ayarlı Apoptosisi.
ATE306555T1 (de) Replikationsdefizienter adenoviraler tnf vektor
ATE362369T1 (de) Selbst-regulierte apoptose von entzuendungszellen durch gentherapie
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
ATE361359T1 (de) Funktion und aktivität des viralen proteins r (vpr)
Katayama et al. Intracellular signal-responsive artificial gene regulation for novel gene delivery
DK0843731T3 (da) Adenovirusvektorer til genterapi
ATE365807T1 (de) Hepatitis b virus vektoren für gentherapie
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells